Davenport & Co
ESPR icon

Davenport & Co’s Esperion Therapeutics ESPR Stock Holding History

Davenport & Co’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$26.5K – 1264
2025
Q3 		$26.5K Hold
10,000
– – ﹤0.01% 1221
2025
Q2 		$9.84K Hold
10,000
– – ﹤0.01% 1200
2025
Q1 		$14.4K Hold
10,000
– – ﹤0.01% 1167
2024
Q4 		$22K Hold
10,000
– – ﹤0.01% 1146
2024
Q3 		$16.5K Sell
10,000
-20,000
-67% -$40.4K ﹤0.01% 1136
2024
Q2 		$66.6K Buy
+30,000
New +$70.6K ﹤0.01% 1103

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Davenport & Co's ESPR Position: Q4 2025 in Review

Davenport & Co sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 10,000 shares — an estimated $26.5K sold.

Davenport & Co first reported a position in ESPR in Q2 2024 and held it in 6 quarters. The position peaked at $66.6K in Q2 2024. 201 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • Davenport & Co reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Davenport & Co sold 10,000 Esperion Therapeutics shares in Q4 2025, an estimated $26.5K.
  • Davenport & Co first reported a position in Esperion Therapeutics in Q2 2024 and held it in 6 quarters.
  • Davenport & Co's Esperion Therapeutics position peaked at $66.6K in Q2 2024.
  • 201 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Davenport & Co's 13F filing for Q4 2025, filed 12 Jan 2026.